Aktis Oncology Announces Pricing of its Upsized Initial Public Offering

Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals

Aktis Oncology’s IPO will support a pipeline of “miniprotein” radioconjugates that could offer advantages over other targeted radiation cancer treatments. In addition to its internal pipeline, Aktis has a discovery partnership with Eli Lilly. The post Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals appeared first on MedCity News.

Aktis Oncology prices upsized US IPO at $18 per share

Jan 8 (Reuters) – Cancer drug ‍developer Aktis Oncology said ‌on Thursday ‌it priced its upsized U.S. initial public ​offering ‍at $18 ​per ​share, raising ‍about $318 million. Aktis is targeting a ‍valuation of up to $945.4 ‍million ‍in ​the ​IPO. (Reporting ⁠by Bipasha ‌Dey in Bengaluru; Editing by Rashmi ⁠Aich)

Aktis raises $318M in 2026’s first biotech IPO

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in the last two years.

Aktis Oncology Announces Pricing of its Upsized Initial Public Offering

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. ("Aktis"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced the pricing of its upsized initial public offering of 17,650,000 shares of its common stock at a price to the public of $18.00 per share. In addition…

Aktis lands biotech's first IPO of 2026, raising $318M for radiopharmaceuticals

An Eli Lilly-partnered radiopharmaceutical startup will kick open the doors for biotech's 2026 IPO class. On Friday, Aktis Oncology will start trading on the Nasdaq. The initial public offering raised $318 million in gross proceeds ...